Business
Formation of Scientific Advisory Board
Formation of Scientific Advisory Board.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n \n \n 6 March 2023\n \n \n \n Roquefort Therapeutics plc\n \n \n \n (\"Roquefort Therapeutics\" or the \"Company\")\n \n \n \n \n \n \n \n \n Formation of Scientific Advisory Board to Support Strategy\n \n \n \n \n Depth of scientific and medical experience\n \n \n \n \n \n \n Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF),\n the Main Market listed biotech company focused on\n developing first in class medicines in the high value and high growth oncology market\n , is pleased to announce the formation of its Scientific Advisory Board (\"SAB\").\n \n \n \n \n \n With the Company's focus on the market niche of the cancers that are resistant to existing medicines, developing innovative, patented medicines to target novel cancer targets or immunotherapies to enhance the body's anti-cancer response, the SAB will initially comprise of Professor Jo Martin, Professor Trevor Jones and Professor Armand Keating, who\n together are a team of researchers, biopharmaceutical innovators and clinicians with an emphasis on linking pre-clinical research, clinical trials, production of medicines and the care of patients\n . The Company aims to use its drug development expertise to complete pre-clinical development to reach valuation milestones for licensing transactions or sale of a clinical program.\n \n \n \n \n \n The SAB will work closely with the Company's Group Chief Scientific Officer, Professor Sir Martin Evans to provide scientific guidance on the Company's strategy as it approaches key pre-clinical milestones and its approach to clinical trials.\n \n \n \n \n \n Professor Jo Martin CBE\n \n \n Professor Martin\n is Professor of Pathology and Deputy Vice Principal Health at Queen Mary, University of London and National Speciality Advisor Pathology NHS England and Improvement. Prof. Martin qualified at Cambridge University and London Hospital Medical College, and has a University of London PhD and Masters in Leadership. She has over 130 published papers including in Nature Group and Science. She is an award winning eCPD app designer and co-founder of Biomoti, a drug delivery development ovarian cancer company. Prof. Martin developed and leads an innovative multi-million pound adaptive learning programme for RCPath and Health Education England. Prof. Martin served as a director on the Board o...